If you have been reading about regulatory status and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-06-30. Numbers and descriptions here follow the published literature rather than marketing material.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Both up and downregulation of miR-324-5p is shown to contribute to various types of cancer. miR-324-5p plays a role in inflammation and tumorigenesis in colorectal cancer through regulation of CUEDC2, which regulates inflammation via interaction with NF-kB signaling. miR-324-5p can inhibit glioma proliferation, suppress hepatocellular carcinoma and nasopharyngeal carcinoma cell invasion, and regulate growth and pathology in multiple myeloma. Additionally, chromosome 17 deletions, which include deletion of miR-324-5p, are present in 10% of multiple myeloma patients and are associated with poorer prognosis. In contrast, overexpression of miR-324-5p in gastric cancer cells reduces cell death and promotes growth and proliferation. miR-324-5p has also been shown to reduce the viability of gastric cancer cells via downregulation of TSPAN8, and miR-324-5p expression increased apoptosis in these same gastric cancer cells.
Amylopectin-based fibers have been fabricated mainly by blending native or modified starches with polymers, plasticizers, cross-linkers, or other additives. Most amylopectin-based fibers are fabricated by electro-wet-spinning, however, the method is demonstrated to be suitable for starches with amylopectin content below 65% and sensitive to amylopectin content of starches. Electrospinning allows for amylopectin to coagulate and form a filament. Fibrous starches induce a more dense material, which can optimize the mechanical properties of starch. Fibers in biomaterials can be used for bone tissue engineering as suitable environment for bone tissue repair and regeneration. Natural bone is a complex composite material composed of an extracellular matrix of mineralized fibers containing living cells and bioactive molecules. Consequently, the use of fibers in biomaterial-based scaffolds offers a wide variety of opportunities to replicate the functional performance of bone. In the last decade, fiber-based techniques such as weaving, knitting, braiding, as well as electrospinning, and direct writing have emerged as promising platforms for making 3D tissue constructs.
NSW EPA QLD Health VIC Department of Health SA EPA TAS Department of Health WA Radiological Council NT Department of Health ACT Health and Community Services Directorate Under the ARPANS Act of 1998, the founding of ARPANSA also established the formation of the Radiation Health and Safety Advisory Council, the Radiation Health Committee and the Nuclear Safety Committee. All of these groups consist of the CEO and an individual to represent the interests of the general public, as well as other specialty members. The functions of the Radiation Health and Safety Advisory Council include providing advice to the CEO, identifying emerging issues relating to radiation protection and nuclear safety and examine matters of community concern, among others. The members include: Two radiation control officers An individual nominated by the chief minister of the NT Eight other members The functions of the Radiation Health Committee include developing and reviewing national policies, codes, and standards for radiation protection, and to consult publicly on them, among others. The members include:
Creatine is an organic acid naturally occurring in the body (and in red meats) that supplies energy to muscle cells for short bursts of energy (as required in lifting weights) via creatine phosphate replenishment of ATP. Scientific studies have shown that creatine supplementation can increase the consumer's strength, energy during performance, muscle mass, and recovery times after exercise. In addition, recent studies have also shown that creatine improves brain function and reduces mental fatigue. Some studies have suggested that consumption of creatine with protein and carbohydrates can have a greater effect than creatine combined with either protein or carbohydrates alone. While generally considered safe, long-term or excessive consumption of creatine may have an adverse effect on the kidneys, liver, or heart and should be avoided if any pre-existing conditions affecting these organs exist.
. in a linear manner. Thus, quinoline-based indicators are one-wavelength dyes - the signal results from monitoring the fluorescence at a single wavelength. Ratiometric measurement of halide concentration is not possible with quinolinium dyes. The kinetics of collision quenching are diffusion-limited only, and these indicators provide submillisecond time resolution. Quinolinium-based dyes are insensitive to physiological changes in pH, but they are prone to strong bleaching and demand ultraviolet excitation, which is harmful for living organisms. Because quinolinium is not occurring in the cells naturally, cell loading is necessary. However, quinolinium-based dyes aren't retained perfectly in the cell and can't be targeted easily to subcellular organelles. Also, they cannot be designed specific to a certain type of cell. The most used quinolinium-based Cl− indicators are 6-methoxy-1-(3-sulfonatopropyl) quinolinium (SPQ), 6-methoxy-N-ethylquinolium Cl− (MEQ), and N-(6-methoxyquinolyl)-acetoethyl ester (MQAE).
Sources: en.wikipedia.org
The major limitation in the development of artificial WBCs is the translation of the technologies into clinical approval and use. Other limitations include the availability of technology necessary to produce artificial WBCs, variability in yield, and difficulties in purifying the particles necessary for standard clinical use. Some studies have also found that these particles may unintentionally target other tissues that are otherwise healthy. The delivery of the therapies faces some difficulties in that too rapid administration might cause systemic side effects, whereas a too slow release would be less effective. A major limitation to polymersomes is that a select number of polymers such as polyethylene glycol and poly(lactic-co-glycolic acid) are approved by the FDA for clinical use. Nanoghosts, or more generally membrane-coated nanoparticles, experience limitations in that cells will have varying degrees of proteins present in their membranes, creating variability and lack of stability in those products. There also is the risk that membrane proteins essential to the biomimetic function of the nanoghosts can become denatured in the manufacturing and storage process. Overall, more studies need to be done on these biomimetic solutions to verify efficacy and safety.
For vitamin B12, the U.S. Recommended Dietary Allowance (RDA) for pregnancy is 2.6 μg/day, for lactation 2.8 μg/day. Determination of these values was based on an RDA of 2.4 μg/day for non-pregnant women, plus what will be transferred to the fetus during pregnancy and what will be delivered in breast milk. However, looking at the same scientific evidence, the European Food Safety Authority (EFSA) sets adequate intake (AI) at 4.5 μg/day for pregnancy and 5.0 μg/day for lactation. Low maternal vitamin B12, defined as serum concentration less than 148 pmol/L, increases the risk of miscarriage, newborn low birth weight and preterm birth. During pregnancy the placenta concentrates B12, so that newborn infants have a higher serum concentration than their mothers. What the mother-to-be consumes during the pregnancy is more important than her liver tissue stores, as it is recently absorbed vitamin content that more effectively reaches the placenta. Women who consume a small percentage of their diet from animal-sourced foods or who by choice consume a vegetarian or vegan diet are at higher risk than those consuming higher amounts of animal-sourced foods of becoming vitamin depleted during pregnancy, which can lead to anemia, and also an increased risk that their breastfed infants become vitamin deficient.
Hydroperoxides or peroxols are compounds of the form ROOH, where R stands for any group, typically organic, which contain the hydroperoxy (also known as perhydroxyl) functional group (−OOH). Hydroperoxide also refers to the hydroperoxide anion (−OOH) (also known as perhydroxyl anion) and its salts, and the neutral hydroperoxyl radical (•OOH) consist of an unbound hydroperoxy group. When R is organic, the compounds are called organic hydroperoxides. Such compounds are a subset of organic peroxides, which have the formula ROOR. Organic hydroperoxides can either intentionally or unintentionally initiate explosive polymerisation in materials with saturated chemical bonds. The O−O bond length in hydroperoxides is about 1.45 Å. The R−O−O angles (R = H, C) are about 110° (water-like). Characteristically, the C−O−O−H dihedral angles are about 120°. The O−O bond is relatively weak, with a bond dissociation energy of 45–50 kcal/mol (190–210 kJ/mol), less than half the strengths of C−C, C−H, and C−O bonds. Hydroperoxides are typically more volatile than the corresponding alcohols:
Cardona completed his PhD at the University of Barcelona (2000–2005), where he studied developmental biology. He then undertook postdoctoral research on Drosophila neuroanatomy at UCLA (2005–2008). Between 2008 and 2011, Cardona was a Group Leader at the Institute of Neuroinformatics, jointly run by the University of Zurich and ETH Zurich. During this period, he developed computational and image-processing methods for neural circuit reconstruction and co-founded two influential open-source platforms that have become widely adopted in the neuroscience community. Cardona joined the Howard Hughes Medical Institute (HHMI) Janelia Research Campus in 2012, serving as Group Leader until 2019. In 2019, he was appointed Programme Leader at the MRC Laboratory of Molecular Biology and Professor at the University of Cambridge, where he leads research on whole-brain connectomics, circuit development, and structure–function relationships in neural systems.
Stage 1: Genetic diversity is created, for example by manual crosses of inbreeding species or mixing of cultivars in outcrossing species. Stage 2: Multiplication of seeds Stage 3: Seeds of each cross are then mixed to produce the first generation of the Composite Cross Population (CCP). The entire offspring is sown to grow and set seed. As the number of plants in the population increases, a proportion of the harvested seed is saved for sowing. Stage 4: The seed can be used for continued evolutionary plant breeding or as a starting point for a conventional breeding effort.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.